Amylin Pharmaceuticals Comments on Shareholder 13-D Filing
January 29 2009 - 12:34PM
PR Newswire (US)
SAN DIEGO, Jan. 29 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) confirmed today that it has
reviewed an amended 13-D filing with the Securities and Exchange
Commission from Amylin shareholder Icahn Capital LP and affiliated
funds announcing their intent to nominate a slate of five directors
to stand for election at the Company's 2009 annual meeting. Amylin
has not yet received the required notice with respect to this
action. Amylin's Corporate Governance Committee is engaged in a
process to recommend a slate for election at the Company's annual
meeting. It is reviewing potential nominees suggested by
shareholders as part of that process, including two individuals
previously discussed with representatives of the Icahn funds. Once
the process has been completed, Amylin's Board of Directors will
formally recommend a slate of nominees that it believes will act in
the best interest of all shareholders. About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and
commercialization of innovative medicines. Amylin has developed and
gained approval for two first-in-class medicines for diabetes,
SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)
injection. Amylin's research and development activities leverage
the Company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in
San Diego, California. Further information on Amylin
Pharmaceuticals is available at http://www.amylin.com/. DATASOURCE:
Amylin Pharmaceuticals, Inc. CONTACT: Alice Izzo of Amylin
Pharmaceuticals, +1-858-642-7272, Web Site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024